News

Nestlé gets rights to CMPA test

3 Jun 2016

Nestlé Health Science has announced that it has entered into a strategic collaboration with DBV Technologies, headquartered in Montrouge, France, aimed at developing and bringing to market DBV’s patch-test tool for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants.

Nestlé Health Science has announced that it has entered into a strategic collaboration with DBV Technologies, headquartered in Montrouge, France, aimed at developing and bringing to market DBV’s patch-test tool for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants.

CMPA is a difficult to diagnose condition, Nestlé notes, which impacts up to 2-3%1 of infants and young children during a critical stage of their development. DBV will leverage its proprietary Viaskin technology platform to develop an innovative, ready-to-use, standardised atopy patch-test.

Today, Nestlé says that CMPA is often missed in the primary care settings due to the non-specific nature of symptoms associated with the condition, such as eczema, reflux, constipation, diarrhoea, crying and others. In 2015, Nestlé Health Science made a first step forward in addressing this difficulty through the Cow’s Milk-related Symptom Score (CoMiSS) awareness tool, developed by leading international experts to help healthcare professionals earlier recognise and assess symptoms that may be related to CMPA in infants and young children.

In the future, Nestlé claims that DBV’s patch-test will enable early and accurate diagnosis of the condition, leading to early nutritional intervention, thereby creating a strong fit with Nestlé Health Science’s nutritional solutions that the company says helps meet the needs of babies and children with food allergies and intolerances (Althéra, Alfaré, Alfamino).

Under the terms of the agreement, DBV is granting Nestlé Health Science exclusive worldwide commercialisation rights of DBV’s diagnostic tool. Nestlé Health Science will make an upfront payment of €10 million. DBV will be responsible for the development stages, including industrialisation and regulatory submissions. Moreover, DBV is eligible to receive development milestones, and if approved, sales milestones and royalty payments on sales.

“This innovation can become the breakthrough diagnostic for CMPA,” said Greg Behar, CEO of Nestlé Health Science. “Early diagnosis and nutritional intervention helps get infants happily back on the path of healthy development, alleviate the anxieties of parents, and reduce healthcare costs. Our reach in the field of paediatric allergy makes Nestlé Health Science an ideal commercialization partner for DVB’s innovative diagnostic patch. This collaboration is another step in our strategy of advancing the role of nutrition through science-based innovation.”

“Improving the lives of those suffering from food allergies is DBV’s mission, and through this exciting partnership with Nestlé Health Science, we are further showcasing our portfolio of potentially transformational and cutting-edge products,” said DBV Technology’s Chief Executive Officer, Dr. Pierre-Henri Benhamou. “Combining DBV’s innovative and proprietary technology with Nestlé Health Science’s global presence and expertise in nutritional therapies is a synergistic approach that we believe has the potential to improve the overall health of our patients.”